Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Commentary: Takeda/Alnylam Best Alliance Deal Of 2008?

This article was originally published in PharmAsia News

Executive Summary

Takeda Pharmaceuticals' May collaboration with U.S.-based Alnylam and its RNAi work was one of the best deals in that class of drugs in 2008. The move even topped Takeda's alliance with Amgen and acquisition of Millennium, both of the United States, earlier in the year. The Anylam alliance also could help the American company gain access to candidate drugs under development by other drug makers and even obtain a partner for its RNAi work elsewhere in Asia. All of that is in addition to the alliance's arrangement for Alnylam to share in marketing rights for up to four Takeda programs of Alnylam's choosing. It also allows Alnylam to finish the year with $500 million during a global financial crisis. (Click here for more

You may also be interested in...



Catchup Capsule: Key APAC Insights You Need To Read

Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.

QUOTED. 4 December. Eric Borin.

Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.

Pfizer’s Expected 2020 COVID-19 Vaccine Production Fell By 50% After Scaleup Delays

Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.

UsernamePublicRestriction

Register

OM002409

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel